EPITARGET
EPITARGET
EPITARGET

EPITARGET - Targets and biomarkers for antiepileptogenesis

Epilepsy is a devastating condition affecting over 50 million people worldwide. Patients with epilepsy suffer from reoccurring unprovoked seizures. The goal of current treatment practice is to enable patients to live unrestricted lives by controlling the seizures with anti-epileptic drugs – Epilepsy cannot be cured to date.

 

In order to someday be able to prevent the development of epilepsy, the multidisciplinary research project EPITARGET is focused on the process leading to epilepsy (epileptogenesis) in adults. The main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and the development of seizures. The central premise and vision is that by using a combinatorial approach to identify appropriate biomarkers that allow the prediction of the disease and by developing effective undefinedanti-epileptogenic therapeutics, patients at risk can be treated before they even have epilepsy. The project will focus on:

 

  • identifying undefinednovel biomarkers and their combinations for epileptogenesis after potentially epileptogenic brain insults in clinically relevant animal models, such as traumatic brain injury (TBI) and status epilepticus (SE);
  • exploring undefinedmultiple basic mechanisms of epileptogenesis and their mutual interactions;
  • and undefinedtranslating these findings towards the clinic by validating biomarkers in human samples accessible to the consortium.

 

On these pages EPITARGET presents the undefinedproject consortium and its undefinedwork plan. You may also find information on EPITARGET undefinedresults and  undefinedmeetings and information undefinedfor patients, as well as the undefinedlatest news about EPITARGET.

 

Short Facts about EPITARGET

 

 

 

 

 

 

 

 

 

 

 

 

 

Home
Menu
Search
Top

Newsletter Subscription

Please fill in the information of your subscription.

 

You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

ARTTIC joins EPITARGET Read more

Social Media

Facebook EPITARGET
Home
Menu
Search
Top